INTRAVITREAL BEVACIZUMAB VERSUS COMBINED BEVACIZUMAB AND TRIAMCINOLONE ACETONIDE FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

RIAZI ESFAHANI M.; AHMADIEH H.; FAGHIHI H.; PIRI N.; TAEI R.; KARKHANEH R.; ALAMI HARANDI Z.; LASHEYEI A.R.; MIRSHAHI AHMAD; NILI AHMADABADI M.; SOHEYLIAN MASOUD; SANAGOU M.

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Journal of Ophthalmic and Vision Research Year:2008 | Volume:3 | Issue:2 Page(s): 95-101

Download Full-Text

View:

380

Download:

130

Cites:

Information Journal Paper

Title

INTRAVITREAL BEVACIZUMAB VERSUS COMBINED BEVACIZUMAB AND TRIAMCINOLONE ACETONIDE FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Author(s)

Keywords

Not Registered.

Abstract

Purpose: To compare the short-term outcomes of intravitreal bevacizumab (IVB) with the combination of IVB and intravitreal triamcinolone acetonide (IVB/IVT) for treatment of neovascular age-related macular degeneration (AMD).Methods: This randomized clinical trial was performed on 92 eyes of 90 patients with subfoveal and juxtafoveal choroidal neovascularization (CNV) secondary to AMD. The eyes were randomly assigned to receive IVB 1.25 mg alone (53 eyes) or in combination with IVT 2 mg (39 eyes). Best-corrected visual acuity (BCVA) and fundus autofluorescence were assessed, and fluorescein angiography (FA) and optical coherence tomography (OCT) were performed at baseline and repeated 6 weeks after treatment. Results: Mean age was 70.6±8.7 (range 50-89) years and 57.7% of the patients were male. BCVA improved from 1.03±0.40 to 0.93±0.38 logMAR (P=0.001) in the IVB group and from 1.08±0.33 to 0.91±0.38 logMAR (P=0.008) in the IVB/IVT group. There was a trend toward greater visual improvement with combined therapy (P=0.06). BCVA improvement was greater in eyes with +1 versus those with +2 (P=0.049) and +3 (P<0.001) fundus autofluorescence at baseline. Mean decrease in central macular thickness was 113±115 mm (P<0.001) in the IVB group versus 53.96±125 mm (P=0.008) in the IVB/IVT group with no intergroup difference (P=0.38). FA showed decreased leakage in 57.4%, increased leakage in 12.8% and no change in 29.8% of patients in the IVB group. Corresponding figures were 60.0%, 5.7% and 34.3% in the IVB/IVT group (P=0.556). Conclusion: Addition of triamcinolone acetonide to bevacizumab for treatment of neovascular AMD does not seem to significantly increase its short-term efficacy. More severe fundus auto fluorescence appears to be predictive of poorer response to treatment.

Cites

References

Cite

APA: Copy

RIAZI ESFAHANI, M., AHMADIEH, H., FAGHIHI, H., PIRI, N., TAEI, R., KARKHANEH, R., ALAMI HARANDI, Z., LASHEYEI, A.R., MIRSHAHI, AHMAD, NILI AHMADABADI, M., SOHEYLIAN, MASOUD, & SANAGOU, M.. (2008). INTRAVITREAL BEVACIZUMAB VERSUS COMBINED BEVACIZUMAB AND TRIAMCINOLONE ACETONIDE FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. JOURNAL OF OPHTHALMIC AND VISION RESEARCH, 3(2), 95-101. SID. https://sid.ir/paper/311290/en

Vancouver: Copy

RIAZI ESFAHANI M., AHMADIEH H., FAGHIHI H., PIRI N., TAEI R., KARKHANEH R., ALAMI HARANDI Z., LASHEYEI A.R., MIRSHAHI AHMAD, NILI AHMADABADI M., SOHEYLIAN MASOUD, SANAGOU M.. INTRAVITREAL BEVACIZUMAB VERSUS COMBINED BEVACIZUMAB AND TRIAMCINOLONE ACETONIDE FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. JOURNAL OF OPHTHALMIC AND VISION RESEARCH[Internet]. 2008;3(2):95-101. Available from: https://sid.ir/paper/311290/en

IEEE: Copy

M. RIAZI ESFAHANI, H. AHMADIEH, H. FAGHIHI, N. PIRI, R. TAEI, R. KARKHANEH, Z. ALAMI HARANDI, A.R. LASHEYEI, AHMAD MIRSHAHI, M. NILI AHMADABADI, MASOUD SOHEYLIAN, and M. SANAGOU, “INTRAVITREAL BEVACIZUMAB VERSUS COMBINED BEVACIZUMAB AND TRIAMCINOLONE ACETONIDE FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION,” JOURNAL OF OPHTHALMIC AND VISION RESEARCH, vol. 3, no. 2, pp. 95–101, 2008, [Online]. Available: https://sid.ir/paper/311290/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops